Passage Bio Inc expected to post a loss of 20 cents a share - Earnings Preview

Passage Bio

28/02/2025 13:33

Passage Bio Inc PASG.OQ PASG.O is expected to show no change in quarterly revenue when it reports  results on March 3 (estimated) for the period ending December 31 2024

​LSEG's mean analyst estimate for Passage Bio Inc is for a loss of 20 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Passage Bio Inc is $5.50​, above​ its last closing price of $0.51. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.21
-0.23
-0.31
Missed
-34.8
Jun. 30 2024
-0.31
-0.31
-0.26
Beat
16.1
Mar. 31 2024
-0.36
-0.36
-0.30
Beat
16.1​
Dec. 31 2023
-0.40
-0.40
-0.30
Beat
25.3
​​Sep. 30 2023
-0.47
-0.46
-0.49
Missed
-7.4
Jun. 30 2023
-0.47
-0.48
-0.44
Beat
8​
Mar. 31 2023
-0.50
-0.50
-0.63
Missed
-27.2
Dec. 31 2022
-0.51
-0.52
-0.49
Beat
6.3

This summary was machine generated February 28 at 13:32 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)